The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.
 
Jeff Porter Sharman
Leadership - US Oncology
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; TG Therapeutics
Speakers' Bureau - Gilead Sciences
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
Expert Testimony - Gilead Sciences
 
Danielle M. Brander
Travel, Accommodations, Expenses - TG Therapeutics
 
Anthony R. Mato
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Regeneron
Research Funding - Abbvie; Acerta Pharma; DTRM; Gilead Sciences; Pharmacyclics; Regeneron; TG Therapeutics
 
Suman Kambhampati
No Relationships to Disclose
 
John M. Burke
Consulting or Advisory Role - Bayer; Celgene; Incyte; Janssen; Pfizer
Travel, Accommodations, Expenses - TG Therapeutics
 
Frederick Lansigan
No Relationships to Disclose
 
Marshall T. Schreeder
Travel, Accommodations, Expenses - TG Therapeutics
 
Scott D. Lunin
No Relationships to Disclose
 
Nilanjan Ghosh
Honoraria - TG Therapeutics
Travel, Accommodations, Expenses - TG Therapeutics
 
Alexander Zweibach
No Relationships to Disclose
 
Mikhail Shtivelband
No Relationships to Disclose
 
Patrick M. Travis
No Relationships to Disclose
 
Jason Claud Chandler
No Relationships to Disclose
 
Kathryn S. Kolibaba
Honoraria - TG Therapeutics
Consulting or Advisory Role - Gilead Sciences; Seagen
Research Funding - Acerta Pharma (Inst); Amgen (Inst); Celgene (Inst); Cell Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Novartis (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - TG Therapeutics
 
Peter Sportelli
Employment - TG Therapeutics
Leadership - TG Therapeutics
Stock and Other Ownership Interests - TG Therapeutics
 
Hari P. Miskin
Employment - TG Therapeutics
Leadership - TG Therapeutics
Stock and Other Ownership Interests - TG Therapeutics
 
Michael S. Weiss
Employment - Fortress Biotech; TG Therapeutics
Leadership - Fortress Biotech; TG Therapeutics
Stock and Other Ownership Interests - Fortress Biotech; TG Therapeutics
 
Ian Flinn
Stock and Other Ownership Interests - RainTree Oncology Services
Research Funding - Acerta Pharma (Inst); Agios (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunogen (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)